| Literature DB >> 20622999 |
Kyung Hwa Jung1, Beizhan Yan, Steven N Chillrud, Frederica P Perera, Robin Whyatt, David Camann, Patrick L Kinney, Rachel L Miller.
Abstract
The application of benzo(a)pyrene (BaP)-toxic equivalent factor to polycyclic aromatic hydrocarbons (PAH) concentrations can provide a more accurate risk assessment from environmental exposure to PAH. We hypothesized that BaP-equivalent toxicity determined following residential air monitoring among young urban children may vary by season. Residential indoor and outdoor air levels of PAH measured over two-weeks in a cohort of 5-6 year old children (n = 260) in New York City were normalized to the cancer and mutagen potency equivalent factor of BaP (BaP = 1). Data are presented as carcinogenic equivalents (BaP-TEQ) and mutagenic equivalents (BaP-MEQ) for the sum of 8 PAH (Sigma(8)PAH; MW >or= 228) and individual PAH and compared across heating versus nonheating seasons. Results show that heating compared to nonheating season was associated significantly with higher (BaP-TEQ)(Sigma8PAH) and (BaP-MEQ)(Sigma8PAH) both indoors and outdoors (p < 0.001). Outdoor (BaP-TEQ)(Sigma8)(PAH) and (BaP-MEQ)(Sigma8PAH) were significantly higher than the corresponding indoor measures during the heating season (p < 0.01). These findings suggest that at levels encountered in New York City air, especially during the heating season, residential exposure to PAH may pose an increased risk of cancer and mutation.Entities:
Keywords: BaP-equivalents; MEF; PAH; TEF; and children; heating season; indoor; outdoor; risk assessment
Mesh:
Substances:
Year: 2010 PMID: 20622999 PMCID: PMC2898023 DOI: 10.3390/ijerph7051889
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
BaP-equivalent carcinogenicity and mutagenicity risks assessed in 5–6 year old residential indoor and outdoor air.
| Σ8PAH | 255 | NA | 0.299 | 0.478 | 0.709 | 0.098–8.348 | NA | 0.376 | 0.590 | 1.325 | 0.069–19.72 |
| BaP | 255 | 1 | 0.121 | 0.198 | 0.363 | 0.015–4.494 | 1 | 0.121 | 0.198 | 0.363 | 0.015–4.494 |
| BaA | 255 | 0.1 | 0.006 | 0.009 | 0.010 | 0.002–0.132 | 0.082 | 0.005 | 0.007 | 0.009 | 0.001–0.108 |
| Chry | 255 | 0.01 | 0.001 | 0.001 | 0.002 | 0.000–0.021 | 0.017 | 0.001 | 0.002 | 0.003 | 0.000–0.036 |
| BbFA | 255 | 0.1 | 0.019 | 0.028 | 0.034 | 0.004–0.346 | 0.25 | 0.047 | 0.069 | 0.084 | 0.010–0.865 |
| BkFA | 255 | 0.1 | 0.006 | 0.010 | 0.013 | 0.002–0.140 | 0.11 | 0.007 | 0.010 | 0.014 | 0.002–0.154 |
| IP | 255 | 0.1 | 0.028 | 0.044 | 0.094 | 0.002–1.400 | 0.31 | 0.087 | 0.136 | 0.291 | 0.006–4.340 |
| DahA | 255 | 5 | 0.083 | 0.180 | 0.212 | 0.055–1.741 | 0.29 | 0.005 | 0.010 | 0.012 | 0.003–0.101 |
| BghiP | 255 | 0.01 | 0.004 | 0.008 | 0.033 | 0.001–0.517 | 0.19 | 0.084 | 0.156 | 0.624 | 0.016–9.828 |
| Σ8PAH | 82 | NA | 0.277 | 0.450 | 0.389 | 0.109–1.932 | NA | 0.360 | 0.528 | 0.454 | 0.062–2.394 |
| BaP | 82 | 1 | 0.091 | 0.133 | 0.133 | 0.016–0.748 | 1 | 0.091 | 0.133 | 0.133 | 0.016–0.748 |
| BaA | 82 | 0.1 | 0.007 | 0.011 | 0.011 | 0.001–0.059 | 0.082 | 0.005 | 0.009 | 0.009 | 0.001–0.048 |
| Chry | 82 | 0.01 | 0.001 | 0.002 | 0.002 | 0.0003–0.008 | 0.017 | 0.002 | 0.004 | 0.003 | 0.001–0.013 |
| BbFA | 82 | 0.1 | 0.039 | 0.048 | 0.043 | 0.006–0.237 | 0.25 | 0.097 | 0.121 | 0.108 | 0.015–0.592 |
| BkFA | 82 | 0.1 | 0.010 | 0.015 | 0.017 | 0.002–0.114 | 0.11 | 0.011 | 0.017 | 0.018 | 0.002–0.125 |
| IP | 82 | 0.1 | 0.027 | 0.035 | 0.031 | 0.003–0.197 | 0.31 | 0.085 | 0.107 | 0.095 | 0.010–0.611 |
| DahA | 82 | 5 | 0.083 | 0.199 | 0.188 | 0.075–1.021 | 0.29 | 0.005 | 0.012 | 0.011 | 0.004–0.059 |
| BghiP | 82 | 0.01 | 0.005 | 0.007 | 0.007 | 0.001–0.039 | 0.19 | 0.087 | 0.126 | 0.126 | 0.010–0.739 |
TEF: toxic equivalency factors for cancer potency relative to BaP (Nisbet and LaGoy, 1992)
MEF: mutagenic potency factor relative to BaP (Durant et al., 1996 and 1999)
BaP-TEQ: Carcinogenic equivalents calculated from the cancer potency relative to BaP (TEF) multiplied by the concentration of PAH in a sample.
BaP-MEQ: Mutagenic equivalents calculated from the mutagenic potency relative to BaP (MEF) multiplied by the concentration of PAH in a sample.
∑8PAH includes benzo(a)pyrene (BaP), benz(a)anthracene (BaA), chrysene/iso-chrysene (Chry), benzo(b)fluoranthene (BbFA), benzo(k)fluoranthene (BkFA), indeno(1,2,3-c,d)pyrene (IP), dibenz(a,h)anthracene(DahA), and benzo(ghi)perylene(BghiP).
Figure 1.Seasonal variations in (a) (BaP-TEQ)∑8PAH and (b) (BaP-MEQ)∑8PAH.
Note: Mann-Whitney test was performed to compare heating season and nonheating concentrations (BaP-TEQ)∑8PAH and (BaP-MEQ)∑8PAH indoors and outdoors. The white and black lines show individual observations, while the white and black area shows the distribution. The dotted line indicates the overall geometric mean and the thicker solid line shows the geometric mean concentration of indoors and outdoors for each season. Mann-Whitney test, **p<0.001. ∑8PAH includes benz(a)anthracene (BaA), chrysene/iso-chrysene (Chry), benzo(b)fluoranthene (BbFA), benzo(k)fluoranthene (BkFA), benzo(a)pyrene (BaP), indeno(1,2,3-c,d)pyrene (IP), dibenz(a,h)anthracene(DahA), and benzo(ghi)perylene (BghiP).
Relationship between indoor and outdoor BaP-equivalent carcinogenicity and mutagenicity risks, stratified by season.
| Average ± SD | Median | Average ± SD | Median | p | ||
|---|---|---|---|---|---|---|
| Heating | (BaP-TEQ)∑8PAH | 0.460 ± 0.365 | 0.346 | 0.558 ± 0.407 | 0.485 | 0.002 |
| (BaP-MEQ)∑8PAH | 0.521 ± 0.448 | 0.388 | 0.660 ± 0.480 | 0.500 | 0.001 | |
| Nonheating | (BaP-TEQ)∑8PAH | 0.515 ± 1.602 | 0.163 | 0.232 ± 0.233 | 0.167 | 0.989 |
| (BaP-MEQ)∑8PAH | 0.975 ± 3.826 | 0.174 | 0.260 ± 0.230 | 0.173 | 0.989 | |
(p<0.01) for Wilcoxon Signed Ranks test.
na: Number for heating season,
nb: Number for nonheating season
Heating season was defined as any sampling that was initiated October 1st through April 30st.